The current collaboration follows previous agreements, initially started in 2004, and extends the partnership between both the two parties for three years.
The tie up will provide support for basic science research at INSpe to further the understanding of multiple sclerosis and offer a match of skills and competencies to bring forward new potential treatments for neurodegenerative diseases.
Under the pact, San Raffaele Scientific Institute will provide its know-how and its models to evaluate the efficacy of the compounds developed by Merck Serono in preclinical and clinical studies in patients.
Merck Serono Global Research and Development executive vice president Bernhard Kirschbaum said that they are pleased to have the opportunity to continue their work with the San Raffaele Scientific Institute and its teams of experts, which will support their efforts to develop translational medicine technologies and models.